Uses of Rocuronium Kabi 10 mg/ml

The drug Rocuronium Kabi 10 mg has the main active ingredient Rocuronium bromide with the strength of 10mg and other excipients in sufficient quantities. Rocuronium Kabi 10 mg drug belongs to the group of muscle relaxants and muscle relaxants indicated in the support of anesthesia in the intensive care unit.

Rocuronium Kabi medicine 10 mg has the main active ingredient is Rocuronium bromide with the content of 10 mg / 1ml and other excipients in a sufficient amount. Rocuronium Kabi 10 belongs to the group of muscle relaxants and muscle relaxants indicated in the support of anesthesia in the intensive care unit. The drug is prepared in the form of a solution for intravenous injection or intravenous infusion. Packaging is a box of 10 vials, each containing 2.5 ml. Pharmacodynamic effects: Active ingredient Rocuronium bromide is a non-depolarizing muscle relaxant with a moderate duration of action and rapid onset of action. The drug's mechanism of action is competition with nicotinic cholinoceptors at motor nerve endings. Pharmacokinetic effects: Following intravenous administration of a single dose of the active ingredient Rocuronium bromide, plasma drug concentrations are expressed in three different phases. Indications: This drug is used to assist in anesthesia for intubation in routine anesthesia and rapid chain anesthesia and to induce muscle relaxation in surgery. Simultaneously, the drug is also used to assist in the intensive care unit (ICU) for intubation and mechanical ventilation.

Rocuronium Kabi is a prescription drug indicated for use in adults and children (including infants to adolescents under 18 years of age). The drug is indicated for use in the following cases:
Intubation during routine induction of anesthesia for adults and children (including infants to adolescents < 18 years), during rapid induction of anesthesia and in the intensive care unit (ICU) for adults. Skeletal muscle relaxation during surgical intervention.

Rocuronium Kabi 10 mg is used intravenously or intravenously. Intravenous infusion technique must be performed by medical personnel. During the infusion, the doctor will assign attention to monitor, evaluate the degree of neuromuscular blockade and the degree of recovery.

There are different dosage indications for each individual user. Dosage is calculated according to Rocuronium bromide.

Intubation Dosage: The standard dose of Rocuronium bromide is 0.8 mg/kg, which is effective enough for intubation within 60 seconds of dosing. Dosage in rapid induction of anesthesia: use the recommended dose of 1.0 mg/kg, followed by intubation within 60 seconds. If a dose of 0.8 mg/kg is used for rapid induction of anesthesia, the patient should be intubated 90 seconds after administration.

The recommended maintenance dose is 0.15 mg/kg. In case of prolonged inhalation anesthesia, the doctor will prescribe a dose reduction to 0.075 - 0.1 mg/kg. The maintenance dose should preferably be administered when the myoclonic reflex has recovered to 25% of baseline. Continuous infusion: If Rocuronium Kabi 10 is to be administered continuously, the infusion should be initiated at a therapeutic dose of 0.6 mg/kg once the neuromuscular blockade begins to reverse. Intravenous anesthesia: The infusion rate is 0.3 - 0.6 mg/kg/hour. Inhalation anesthesia: The infusion rate is 0.3 - 0.4 mg/kg/hour. During infusion, it is necessary to pay close attention to the person using the drug, especially to monitor the neuromuscular blockade. Care should be taken to adjust the dose in pregnant women, pediatric patients, renal failure or elderly patients.

Before use, bring Rocuronium Kabi 10 mg to room temperature or room temperature. If the drug is diluted with 0.9% sodium chloride solution and 5% glucose solution, it should be used immediately after dilution. If not used immediately, must be refrigerated at a temperature of 2 - 8 degrees C with a storage time not exceeding 24 hours. Check the vial before use: It is only allowed to use the medicine if the solution is clear, there are no abnormal molecules.

During the use of Rocuronium Kabi 10 mg, you may experience some common undesirable effects such as pain, inflammation at the injection site, especially during rapid induction of anesthesia, using propofol as an anesthetic agent. and prolong the relaxation time. Rare adverse effects such as tachycardia, hypotension, circulatory failure, shock, bronchospasm, dyspnea, respiratory failure. Some people may experience allergic reactions including rash, erythema, urticaria, itching (caused by possible histamine release). Undetermined incidence: Musculoskeletal disorders: Skeletal muscle weakness, steroid myopathy, neuromuscular blockade lasting longer than necessary and anaphylactic reactions.

Aminoglycosides, lincosamides, polypeptide antibiotics, acylamino-penicillins, tetracyclines, metronidazol with high therapeutic doses. Diuretics, thiamin, MAOIs, quinidine and quinine isomers, protamines, adrenergic inhibitors, magnesium salts, calcium blockers, lithium may interact with Rocuronium Kabi 10. Increased effects: Halogenated anesthetics, specifically Rocuronium Kabi 10, cause interactions when using high doses of thiopental, methohexital, ketamine, fentanyl, gammahydroxybutyrate, etomidat and propofol; other non-depolarizing muscle relaxants or previous use or treatment with suxamethonium. Long-term use of Rocuronium Kabi 10 mg with corticosteroids may prolong the duration of action of rocuronium and myopathy. Reduce the impact when using the drug Rocuronium Kabi 10 mg with Neostigmin, edrophonium, pyridostigmin, aminopyridine derivatives; previous prolonged use of corticosteroids, phenytoin or carbamazepine; noradrenaline, azathioprine; theophyllin, CaCl2, KCl; protease inhibitors.

Active ingredient Rocuronium bromide is contraindicated for people with hypersensitivity to Rocuronium active ingredient or to bromide ion or to any ingredient of the drug.

Rocuronium Kabi 10 should only be used after complete recovery of the neuromuscular blockade induced by suxamethonium. People with liver/bile disease or kidney failure; cardiovascular diseases, advanced age, edema; neuromuscular disease or after poliomyelitis. Pregnant women: Use this drug only when absolutely necessary and depending on the benefit versus risk, breast-feeding: weigh the benefits and risks. Rocuronium Kabi 10 mg is not recommended when operating hazardous machinery or driving within 24 hours of full recovery.

Drug use in pregnant and lactating women:
Information on the use of Rocuronium Kabi 10 in pregnant women is very limited. There are no data on the use of Rocuronium Kabi 10 mg in nursing mothers. Use when driving and handling machines:
Rocuronium Kabi 10 mg has a significant effect on the ability to drive and use machines. It is therefore not recommended to operate hazardous machinery or drive a vehicle for 24 hours after complete recovery from the neuromuscular blocking effects of Rocuronium Kabi 10.

Store the drug Rocuronium Kabi 10 in the refrigerator at a temperature of 2 - 8 degrees C. If there is no cold storage condition: Store at a temperature not exceeding 30 degrees C, but then the shelf life of this medicine is only 12 weeks, after which the medication must be discarded. Do not put Rocuronium Kabi 10 in the refrigerator after it has been stored in the open air. Do not store the drug when Rocuronium Kabi 10 has expired. Above is all information about Rocuronium Kabi 10 mg drug, patients need to carefully read the instructions for use, consult a doctor / pharmacist before using. Absolutely do not arbitrarily buy Rocuronium Kabi 10 to treat diseases at home, because there may be unwanted side effects on health.